Overview

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Status:
Completed

Trial end date:
2021-05-28

Target enrollment:

Participant gender:

Summary

To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low dose cytarabine in patients >= 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction therapy

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Cytarabine